Sign inJoin waitlistJoin the waitlist

Vinay Puduvalli

Co-Program Director, Cancer Neuroscience Program · University of Texas M D Anderson Cancer Center

Credentials: · · · ·

History

Cancer Neuroscience Program · University of Texas M D Anderson Cancer Center
Present
Neuro-Oncology Department · University of Texas M D Anderson Cancer Center
Present
Brain Tumor Center · University of Texas M D Anderson Cancer Center
Present

Clinical Neurophysiology
1998–1999
University of Texas M D Anderson Cancer Center
1996–1998
The University of Texas Health Sciences Center
1993–1996
Preliminary Internal Medicine
Texas Tech University Health Sciences Center at Amarillo
1992–1993
National Institute of Mental Health & Neurosciences
1990–1991
Church of South India Hospital
1989–1990
MS Ramalah Medical College Hospitals
1990
Doctor of Medicine
1985–1989

Research

Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2020 · 405 citations
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma
Journal of Clinical Oncology · 2010 · 405 citations
Tumor microenvironment in glioblastoma: Current and emerging concepts
Review · Neuro-Oncology Advances · 2023 · Last of 4 authors · Corresponding · 329 citations

Pierre Giglio
24 papers
MG
Morris Groves
21 papers
CC
Charles Conrad
20 papers
VL
Victor Levin
20 papers
John de Groot
18 papers
Howard Colman
17 papers · 7 as a resident
Frederick Lang
14 papers
Kenneth Aldape
13 papers
PW
Patrick Wen
13 papers
Iyad Alnahhas
10 papers · 2 as a fellow
Gregory Fuller
9 papers
Marta Penas-Prado
9 papers

Grants

The University of Texas MD Anderson Cancer Center Support Grant (CCSG)
National Cancer Institute · P30
Project lead · $274.5K · University of Tx Md Anderson Can Ctr
1996–2031
A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma
National Cancer Institute · R01
Contact PI · $2.9M · University of Tx Md Anderson Can Ctr
2019–2026
Patient Oriented Research Program in Neuro-Oncology
National Cancer Institute · K24
Contact PI · $580.3K · Ohio State University
2012–2017
Efficacy and Toxicity of TRAIL Against Gliomas
National Cancer Institute · R01
Contact PI · $1M · University of Tx Md Anderson Can Ctr
2006–2011

Clinical trials

Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma
Principal investigator · Withdrawn · Phase 2
M.D. Anderson Cancer Center
2024
Pembrolizumab in Treating Patients With Recurrent Glioblastoma
Principal investigator · Active not recruiting · Phase 2
M.D. Anderson Cancer Center
2015–2026
DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors
Principal investigator · Completed · Phase 1
DNAtrix, Inc.
2014–2018
Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy
Principal investigator · Terminated · Phase 1
M.D. Anderson Cancer Center
2011–2025